Gilead Sciences, Inc. $GILD Shares Newly Bought by Danica Pension Livsforsikringsaktieselskab

Danica Pension Livsforsikringsaktieselskab bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,789 shares of the biopharmaceutical company’s stock, valued at approximately $863,000.

Several other institutional investors and hedge funds have also bought and sold shares of GILD. Danske Bank A S increased its stake in shares of Gilead Sciences by 27.1% in the third quarter. Danske Bank A S now owns 1,068,347 shares of the biopharmaceutical company’s stock worth $159,237,000 after buying an additional 227,947 shares during the period. Drive Wealth Management LLC raised its holdings in Gilead Sciences by 1.9% during the 3rd quarter. Drive Wealth Management LLC now owns 4,515 shares of the biopharmaceutical company’s stock valued at $673,000 after buying an additional 86 shares during the last quarter. Silver Oak Advisory Group Inc. purchased a new stake in Gilead Sciences during the 3rd quarter valued at $206,000. Cornerstone Advisory LLC purchased a new stake in Gilead Sciences during the 3rd quarter valued at $214,000. Finally, Aberdeen Group plc boosted its position in Gilead Sciences by 3.1% during the 3rd quarter. Aberdeen Group plc now owns 1,034,855 shares of the biopharmaceutical company’s stock valued at $154,245,000 after buying an additional 31,340 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 0.1%

Gilead Sciences stock traded up $0.13 during mid-day trading on Friday, reaching $168.08. 3,637,311 shares of the company traded hands, compared to its average volume of 6,772,945. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. The firm’s 50 day moving average price is $155.10 and its 200 day moving average price is $141.80. The firm has a market capitalization of $208.48 billion, a price-to-earnings ratio of -53.19 and a beta of 0.35. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $176.58.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same period in the prior year, the business earned $2.47 EPS. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences, Inc. will post -0.98 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. Gilead Sciences’s payout ratio is currently -103.80%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel O’Day sold 102,619 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $175.16, for a total transaction of $17,974,744.04. Following the sale, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at approximately $96,632,794.28. The trade was a 15.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Wettan Keeley M. Cain sold 3,399 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the transaction, the executive vice president owned 5,360 shares in the company, valued at $879,629.60. This trade represents a 38.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 242,709 shares of company stock valued at $39,503,427 over the last quarter. 0.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on GILD. Bank of America boosted their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research report on Tuesday, October 20th. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Morgan Stanley raised their target price on Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. BMO Capital Markets restated an “outperform” rating and set a $184.00 price target on shares of Gilead Sciences in a report on Friday, October 30th. Finally, Scotiabank upped their price target on Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a research report on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $171.07.

Key Gilead Sciences News

These are some of the GILD news items that stood out recently:

• Positive Sentiment: Zacks Research raised several forecasts, including FY2027 EPS to $9.42 from $9.36 and FY2028 EPS to $9.69 from $9.66. It also made small upward adjustments to quarterly estimates. The revisions suggest slightly improved expectations, though the analyst’s Hold rating tempers the signal.
• Positive Sentiment: Coverage points to momentum in Gilead’s HIV franchise: Yeztugo sales are described as surging, Biktarvy remains a market leader, and the expanding pipeline could support longer-term growth. Read More..
• Neutral Sentiment: Gilead announced a partnership with TelevisaUnivision to promote HIV-prevention awareness at the Latin GRAMMY Awards. It may build awareness, but the announcement does not specify a direct near-term financial impact. Read More..

Gilead Sciences Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.